


Prenatal genetic testing non-invasive

Detection in maternal blood
of complete chromosomal
alterations, and CNV¹
(deletions and duplications)
in all chromosomes of the
future baby.



SafeBaby[®]

Detection of aneuploidy
in chromosomes 13, 18, 21,
X and Y

SafeBaby[®] Gold

Detection of aneuploidies, deletions
and duplications in all chromosomes

SafeBaby[®] is a highly accurate non-invasive prenatal test (NIPT) that detects the risk of aneuploidy in fetal chromosomes 13, 18, 21, X and Y by studying the fetal DNA present in maternal blood. SafeBaby[®] also provides information on foetal sex.


SafeBaby[®] Gold detects aneuploidy and CNV1 in all fetal chromosomes. Furthermore, by extending the study of chromosomal alterations to all chromosomes, SafeBaby[®] Gold is a simple alternative for the study of possible reasons for gestational losses.




Non-invasive prenatal testing

SafeBaby® Gold

Detection of less common chromosomal alterations Aneuploidies and CNVs (deletions and duplications) in all chromosomes.



16% of the chromosomal alterations are not on chromosomes 21, 18, 13, X and Y.



It also detects less common chromosomal abnormalities not covered by other NIPT technologies.

SafeBaby® Gold detects and reports trisomies on all 24 chromosomes


		Chromosome	Sensitivity [%]	Specificity [%]
SafeBaby®	SafeBaby®	Down's Syndrome [21]	>99,9	99,9
		Edward's syndrome [18]	>99,9	99,9
		Patau syndrome [13]	>99,9	99,9
		Monosomy X	95,0	99,9
		XX	>99,9	99,8
		XY	>99,9	>99,9
	SafeBaby® Gold	Resto de cromosomas [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 19, 20 y 22]	96,4	99,8
		Deletions and duplications	Sensitivity [%]	Specificity [%]
		CNV ¹	74,1	99,8

SafeBaby® and SafeBaby® Gold are the most accurate tests available on the market, with the lowest failure rate (<0.1%) and the lowest false positive rate (<0.1%).

The process



1. CNV: Copy Number Variations [CNV] refers to structural variations in certain DNA segments compared to a reference genome.



The Illumina® and VeriRef Gold® are registered trademarks in the USA and other countries. Powered by the USA and other countries. The non-invasive prenatal test (NIPT) based on the analysis of circulating free fetal DNA is a screening test, not a diagnostic test. The test should not be used in isolation for diagnosis. Additional tests are necessary before making an irreversible decision about pregnancy.





In which cases are SafeBaby[®] and/or SafeBaby[®] Gold indicated?

All pregnant women can benefit from the Safebaby advanced prenatal test.
This test is especially indicated:

- Advanced maternal age
- Ultrasound findings suggestive of chromosomal abnormalities
- Previous history of pregnancy with chromosomal abnormality
- High-risk biochemical screening result
- Couples wishing to rule out chromosomal abnormalities
- As a first-level approach to assessing early pregnancy losses
- Couples who have experienced recurrent miscarriages

Why choose SafeBaby[®] and/or SafeBaby[®] Gold?

- It allows the **study of possible gestational losses and a better follow-up of the pregnancy.**
- It has the **lowest rate of not obtaining results: <0.1%.**
- **Fast**, results in the shortest period of time.
- It **quantifies** in a detailed and very sensitive way the **foetal fraction** of each sample.
- For **high-risk results**, immediate notification and **FREE CONFIRMATION by QF-PCR or CGH Array** from an amniotic fluid sample.
- **Suitable for any BMI, ethnicity, IVF and egg donation.**
- **Test with the highest number of publications that endorse it** (SafeBaby[®] and SafeBaby[®] Gold by ILLUMINA).
- **All equipment:** platform, software and consumables **with CE-IVD marking.**
- **Technology: MPS-Massive Parallel Sequencing** (whole genome sequencing). It will allow new developments to be incorporated in the future.
- **Made entirely in Spain.**
- **SafeBaby[®] Gold** also detects **aneuploidies and CNV¹ (deletions and duplications) in all chromosomes.**

When does it apply?

It can be performed on patients as early as the **10th week** of pregnancy.

